Openbookopenbook
Equity
Bioventix(BVXP)
GBX --+0.00%
Reward54Moderate
Risk18Low
📊75%Data
Strong 59% profit margin · 9.1% dividend yield · Revenue down 9% YoY
BVXP
+0.0 · +0.00%
GBX · LSE
Bioventix | Healthcare
Defensive Anchor
Market Cap:87.52M
ℹ️
Reward Rating
54
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
18
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on BVXP to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 3900p.

What is Bioventix?

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.

BVXP · Verdict

Moderate reward · low risk

BVXP stands out on cash flow and balance sheet, but watch the growth signal.

Based on 88% data coverage

BVXP · Verdict

What’s working & what to watch

Strengths 5

  • Cash flow95/100

    53% free-cash-flow margin

  • Balance sheet89/100

    Current ratio 9.17

  • Profitability87/100

    58% net margin · 67% ROE

  • Valuation81/100

    P/E 11.4×

  • Volatility80/100

    Top decile vs peers

Watchouts 1

  • Growth30/100

    Rev +3.8% CAGR · earnings -0.4%

Model-based scoring. For information only — not financial advice.

What is Bioventix?

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 87.52M, and a P/E ratio of 11.9x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (54)

The scoring profile indicates limited reward potential at this time, with profitability and valuation offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap87.52M
P/E Ratio11.8794
Dividend Yield9.09%
52 Week High2801.535
52 Week Low1251.4667
Last AnnualJune
IPO DateN/A
IncorporatedUK
Shares Outstanding5M
No. of Employees12
IndustryBiotechnology
ExchangeLSE
Beta0.484
CurrencyGBX · Reports in GBP
Websitewww.bioventix.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.